Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias

被引：2

作者：

Schupp, Tobias ^{[1
]}

Behnes, Michael ^{[1
]}

Abumayyaleh, Mohammad ^{[1
]}

Weidner, Kathrin ^{[1
]}

Mashayekhi, Kambis ^{[2
]}

Bertsch, Thomas ^{[3
]}

Akin, Ibrahim ^{[1
]}

机构：

[1] Heidelberg Univ, Univ Med Ctr Mannheim UMM, DZHK German Ctr Cardiovasc Res Partner Site Heide, Fac Med Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

[2] Univ Heart Ctr Freiburg, Dept Cardiol & Angiol 2, D-79189 Bad Krozingen, Germany

[3] Paracelsus Med Univ, Inst Clin Chem, Lab Med & Transfus Med, Nuremberg Gen Hosp, D-90419 Nurnberg, Germany

来源：

JOURNAL OF CLINICAL MEDICINE | 2022年 / 11卷 / 05期

关键词：

ventricular tachycardia; ventricular fibrillation; mortality; ACE inhibitor; ARB; medical treatment; pharmacological drugs; SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; HEART-FAILURE; MORTALITY; DYSFUNCTION; ARRHYTHMIAS; PREVENTION; MORBIDITY; RISK;

D O I：

10.3390/jcm11051460

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Data investigating the prognostic value of treatment with angiotensin converting enzyme inhibitors (ACEi) and receptor blockers (ARB) usually focusses on patients presenting with heart failure (HF) or acute myocardial infarction (AMI). However, by preventing adverse cardiac remodeling, ACEi/ARB may also decrease the risk of ventricular tachyarrhythmias and sudden cardiac death (SCD). Although ventricular tachyarrhythmias are associated with significant mortality and morbidity, only limited data are available focusing on the prognostic role of ACEi/ARB, when prescribed for secondary prevention of SCD. Therefore, this study comprehensively investigates the role of ACEi versus ARB in patients with ventricular tachyarrhythmias. A large retrospective registry was used including consecutive patients with episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2015. The primary prognostic outcome was all-cause mortality at three years, secondary endpoints comprised a composite arrhythmic endpoint (i.e., recurrences of ventricular tachyarrhythmias, ICD therapies and sudden cardiac death) and cardiac rehospitalization. A total of 1236 patients were included (15% treated with ARB and 85% with ACEi) and followed for a median of 4.0 years. At three years, ACEi and ARB were associated with comparable long-term mortality (20% vs. 17%; log rank p = 0.287; HR = 0.965; 95% CI 0.689-1.351; p = 0.835) and comparable risk of the composite arrhythmic endpoint (HR = 1.227; 95% CI 0.841-1.790; p = 0.288). In contrast, ACEi was associated with a decreased risk of cardiac rehospitalization at three years (HR = 0.690; 95% CI 0.490-0.971; p = 0.033). Within the propensity score matched cohort (i.e., 158 patients with ACEi and ARB), ACEi and ARB were associated with comparable long-term outcomes at three years. In conclusion, ACEi and ARB are associated with comparable risk of long-term outcomes in patients presenting with ventricular tachyarrhythmias.

引用

页数：11

共 21 条

[1]

Al-Khatib SM, 2018, CIRCULATION, V138, pE210, DOI [10.1161/CIR.0000000000000548, 10.1161/CIR.0000000000000549]

[2] Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE Multicenter Study) [J].